终末期肾病血液透析患者接种新冠病毒灭活疫苗的临床研究

Clinical Study of Inactivated COVID-19 Vaccine in End-Stage Renal Disease Hemodialysis Patients

目的:研究终末期肾病维持性血液透析患者接种新冠病毒灭活疫苗的安全性。方法:选取2021年1-9月武汉大学附属中南医院和远安县人民医院血液净化科收治的已接种新冠病毒灭活疫苗2剂的382例终末期肾病维持性血液透析患者作为试验组,随机选取同期382名已接种新冠病毒灭活疫苗2剂的健康人群作为对照组,比较两组不良反应发生率。结果:两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:终末期肾病维持性血液透析患者接种新冠病毒灭活疫苗后的不良反应暂时、轻微,发生率低,安全性较高。

Objective:To study the safety of inactivated COVID-19 vaccine in patients on maintenance hemodialysis for endstage renal disease.Methods:382 end-stage renal disease maintenance hemodialysis patients who had received 2 doses of inactivated COVID-19 vaccine admitted to the Department of Hemodialysis,Zhongnan Hospital of Wuhan University and Yuan’an People’s Hospital from January to September 2021 were selected as the test group.Randomly selected 382 healthy people who had received 2 doses of inactivated COVID-19 vaccine during the same period were used as the control group to compare the incidence of adverse reactions in the two groups.Results:There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The adverse reactions in patients on maintenance hemodialysis for end-stage renal disease were temporary and mild with low incidence and high safety after inactivated COVID-19 vaccine.